Targeting the Microbiome for Disease Diagnosis and Therapy : New Frontiers for Personalized Medicine

Background: The gut microbiota is emerging as a pivotal player in the pathogenesis of many non-communicable diseases. Thus, it has been proposed as a new diagnostic and therapeutic target.Aim and scope: This Special Issue will focus on the microbiome as a potential target of new personalized therapi...

Full description

Saved in:
Bibliographic Details
Sonstige:
Year of Publication:2022
Language:English
Physical Description:1 electronic resource (280 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 05004nam-a2201213z--4500
001 993573552604498
005 20231214133206.0
006 m o d
007 cr|mn|---annan
008 202212s2022 xx |||||o ||| 0|eng d
020 |a 3-0365-5611-7 
035 |a (CKB)5470000001631723 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/94490 
035 |a (EXLCZ)995470000001631723 
041 0 |a eng 
100 1 |a Laterza, Lucrezia  |4 edt 
245 1 0 |a Targeting the Microbiome for Disease Diagnosis and Therapy  |b New Frontiers for Personalized Medicine 
246 |a Targeting the Microbiome for Disease Diagnosis and Therapy  
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2022 
300 |a 1 electronic resource (280 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a Background: The gut microbiota is emerging as a pivotal player in the pathogenesis of many non-communicable diseases. Thus, it has been proposed as a new diagnostic and therapeutic target.Aim and scope: This Special Issue will focus on the microbiome as a potential target of new personalized therapies or diagnostic tools.History: In recent decades, the gut microbiome has been deeply investigated, and many studies have provided new information on the role of dysbiosis in many gastrointestinal and extra-gastrointestinal diseases. Recently, in addition to its phylogenetic characterization, new information has become available regarding the function of the gut microbiota, thanks to proteomic and metabolomic analyses.Cutting-edge research: The therapeutic modulation of the gut microbiota based on different strategies, including diet modification, antibiotics, prebiotics, probiotics, and, last but not least, fecal microbiota transplantation, has been tested for the treatment of various diseases. Recently, the possible applications and modalities of gut microbiota modulation have been increasingly expanding.We have collected original clinical or pre-clinical research papers and reviews focusing on the use of the microbiome for disease diagnosis, monitoring, or therapy and suggesting new possible gut microbiota-based approaches for personalized care. 
546 |a English 
650 7 |a Medicine  |2 bicssc 
653 |a Graves-Basedow's diseases 
653 |a Hashimoto's thyroiditis 
653 |a autoimmunity 
653 |a gut microbiota 
653 |a irritable bowel syndrome 
653 |a microbiota 
653 |a microbiome 
653 |a food components 
653 |a nutrients 
653 |a hematopoietic stem cell transplantation 
653 |a fecal microbiota transplantation 
653 |a aGvHD 
653 |a antibiotic-resistant bacteria 
653 |a cystic fibrosis 
653 |a rabbits 
653 |a intestinal dysbiosis 
653 |a feces microbiome 
653 |a beta-blocker 
653 |a hemodialysis 
653 |a next-generation sequencing 
653 |a propensity score matching methods 
653 |a violin plots 
653 |a random sampling 
653 |a analytical reproducibility 
653 |a fecal matter transplantation 
653 |a data disease subtypes 
653 |a personalized medicine 
653 |a maltodextrin 
653 |a dip test 
653 |a gallstone disease 
653 |a 16S rDNA gene diversity 
653 |a blood biochemical characteristics 
653 |a mesothelioma 
653 |a 16S RNA sequencing 
653 |a species 
653 |a probiotics and gut disease 
653 |a probiotics and acute diverticulitis 
653 |a probiotics and diverticular disease 
653 |a probiotics mechanism of action 
653 |a IgA Nephropathy 
653 |a rifaximin 
653 |a α1KI-CD89Tg mice 
653 |a children 
653 |a intermittent hypoxemia 
653 |a obstructive sleep apnea 
653 |a tonsil 
653 |a weight status 
653 |a oral microbiota 
653 |a rheumatology diseases 
653 |a biomarkers 
653 |a artificial intelligence 
653 |a machine learning 
653 |a rheumatoid arthritis 
653 |a Sjogren's syndrome 
653 |a systemic lupus erythematosus 
653 |a endometrial cancer 
653 |a endometrial microbiome 
653 |a gut microbiome 
653 |a dysbiosis 
653 |a estrogen metabolism 
653 |a estrobolome 
653 |a inflammation 
653 |a antitumour treatment 
653 |a prebiotics 
653 |a probiotics 
653 |a schizophrenia 
653 |a depression 
653 |a anxiety 
653 |a functional genes 
653 |a thymoma 
653 |a genera 
653 |a driver mutation 
653 |a cardiovascular diseases 
653 |a critically ill 
653 |a intestinal permeability 
653 |a recurrent cystitis 
776 |z 3-0365-5612-5 
700 1 |a Laterza, Lucrezia  |4 oth 
906 |a BOOK 
ADM |b 2023-12-15 05:46:15 Europe/Vienna  |f system  |c marc21  |a 2023-01-09 04:44:33 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5341785350004498&Force_direct=true  |Z 5341785350004498  |b Available  |8 5341785350004498